Day: August 14, 2023

LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) — Ferroglobe PLC (NASDAQ: GSM) (“Ferroglobe”, the “Company”, or the “Parent”), a leading producer globally of silicon metal, silicon-based and manganese-based specialty alloys, today announced financial results for the second quarter 2023. FINANCIAL HIGHLIGHTSReported Q2-23 revenue of $456.4 million, up 14% over the prior quarter Q2-23 adjusted EBITDA of $105.7 million, up 136% over the prior quarter Improved Q2-23 adjusted EBITDA margin to 23.2% versus 11.2% in Q1-23 Q2-23 Adjusted EPS was $0.30 versus $0.05 in Q1-23 Gross debt was $400.1 million in Q2-23, flat versus the prior quarter and down $100 million from a year-ago quarter Net debt declined to $37 million, down from $55 million in Q1-23 and $194 million in Q2-22 $100 million available from our ABL facility completely undrawn in...

Reported 100 basis point expansion in 2023 YTD EBITDA Margin1   Expanded U.S. based freight-brokerage operations to seven locations, adding a new location in Jacksonville, Florida Announced strategic U.S.-based asset acquisition of Crane Transport, Inc. (“Crane”), positioning the Company to enhance its service offerings with Titanium branded trucks in major U.S. transportation hubs of Georgia and AlabamaBOLTON, Ontario, Aug. 14, 2023 (GLOBE NEWSWIRE) — Titanium Transportation Group Inc. (“Titanium” or the “Company”) (TSX:TTNM, OTCQX:TTNMF), is pleased to report its financial results for the three and six-month period ended June 30, 2023. All amounts are in Canadian currency. Q2 2023 Financial Highlights compared with Q2 2022Consolidated revenue of $100.4 million, compared to $136.2 million in Q2 2022 Consolidated...

WALL, N.J. , Aug. 14, 2023 (GLOBE NEWSWIRE) —  BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) and Identity-Bound Biometric (IBB) solutions, today reported results for its second quarter ended June 30, 2023 (Q2’23). BIO-key will host an investor call tomorrow at 10:00 a.m. ET (details below) to review its results and outlook. Highlights:Q2’23 revenues of $1.9M approximated Q2’22 revenue of $1.9M, despite delays in the closing of certain larger customer opportunities, including a $0.3M defense ministry order signed in early Q3’23. Revenue rose 29% in the first six months of FY’23 over the prior-year period, due to a record start in Q1’23. Continued PortalGuard IDaaS Traction Supporting Healthcare Migrations to Epic Hyperdrive, including Dayton Children’s...

CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) — AppTech Payments Corp. (“AppTech”) (NASDAQ: APCX), an innovative Fintech company powering seamless commerce between businesses and consumers, today announced results for its second quarter ended June 30, 2023. The financial statements and 10-Q are available on sec.gov. Second Quarter and Year-to-Date 2023 Financial HighlightsRevenue was approximately $134 thousand for the three months ended June 30, 2023, up 9% compared to $123 thousand for the three months ended June 30, 2022. The increase was principally driven by higher transaction volume. Revenue was approximately $223 thousand for the six months ended June 30, 2023, compared to $227 thousand for the prior-year period. The slight decrease was principally driven by an adjustment in our revenue related to a processor. Cash...

VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce its financial results for the three months ended June 30, 2023 (“Q2 2023”) and six months ended June 30, 2023. Q2 2023 HighlightsRevenue of $14.1 million in Q2 2023 and $26.5 million for the six months ended June 30, 2023, up 27.7% and 27.2%, respectively, compared to the same periods in 2022. Adjusted revenue1 of $15.4 million in Q2 2023 (DIV’s strongest adjusted revenue1 quarter to date since adopting its multi-royalty strategy in 2013) and $29.0 million for the six months ended June 30, 2023, up 25.1% and 24.5%, respectively, compared to the same periods in 2022. Distributable cash1 of $9.8 million in Q2 2023 and $18.6 million for the six months ended June 30,...

PHOENIX, Aug. 14, 2023 (GLOBE NEWSWIRE) — Mobivity Holdings Corp. (OTCQB:MFON), a global provider of personalized reward solutions that drive customer acquisition, frequency, and spend, today announced financial results for the second quarter (“Q2”) ended June 30, 2023. Q2 2023 Financial HighlightsRevenues of $1.9 million remained consistent compared to $1.9 million in Q2 2022. Gross profit margin of 26% compared to 36% in Q2 2022. Operating expenses of $2.5 million compared to $2.4 million in Q2 2022. Net loss was $2.3 million compared to a net loss of $2.0 million in Q2 2022. Adjusted EBITDA, excluding certain non-cash expenses, was ($1.8) million compared to ($1.1) million in Q2 2022. Cash and cash equivalents of $529,000 as of June 30, 2023 compared to $427,000 as of December 31, 2022.Recent Business HighlightsAppointed...

  • Revenue of $82.1 million for Q2 2023 and $159.4 million for FY 2023  • Gross profit (exclusive of depreciation and amortization) of $22.6 million for Q2 2023 and $41.6 million for FY 2023  • Net income of $1.2 million for Q2 2023 and net loss of $30.8 million for FY 2023  • Media margin of $25.9 million for Q2 2023 and $47.9 million for FY 2023  • Adjusted EBITDA of $5.6 million for Q2 2023 and $6.0 million for FY 2023  • Adjusted net income of $1.0 million for Q2 2023 and adjusted net loss of $1.7 million for FY 2023NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, today reported financial results for the second quarter ended June 30, 2023. Don Patrick, Fluent’s Chief Executive Officer, commented, “Our second quarter results...

Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive Officer and Monic Stuart, M.D., MPH, as Chief Medical Officer to spearhead Marker’s restructuring efforts and guide clinical advancement of Marker’s multiTAA-specific T cell technology Announced encouraging non-clinical data from MT-401 program demonstrating increased anti-tumor activity against an acute myeloid leukemia (AML) cell line after treatment with hypomethylating agents (HMA) Received $2 million of non-dilutive funding from National Institute of Health (NIH) to support MT-401 program for treatment of patients with AML Commenced treatment of first patient with lymphoma with MT-601 multiTAA-specific T cell-based therapy in Phase 1...

Second-quarter net revenue of $82.6 million Second-quarter gross margin of 23.3% and Variable Marketing Margin (VMM) of 27.4%CLEARWATER, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) — Digital Media Solutions, Inc. (NYSE: DMS), a leading provider of technology-enabled digital performance advertising solutions connecting consumers and advertisers, today announced financial results for the quarter ended June 30, 2023. DMS serves 379 scaled enterprise customers and nearly 4,406 SMBs across the P&C Insurance, Health Insurance, Ecommerce, Career and Education and Consumer Finance verticals with digital performance marketing solutions. “Our second quarter results reflect continued market challenges we are experiencing. Despite a decrease in net revenue and adjusted EBITDA due to the challenging business cycle, gross profit margin for...

SAN DIEGO, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) — Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a medical technology company that creates blood purification devices to overcome clearly defined limitations in healthcare, today announces financial results for the second quarter ended June 30, 2023. During the quarter, the Company continued its focus to initiate first-in-human studies of Sigyn TherapyTM, a medical device designed to treat pathogen-associated inflammatory disorders that are not addressed with drug therapies. The initial treatment indication is directed toward end-stage renal disease (ESRD) patients suffering from endotoxemia, a condition that is highly prevalent and associated with increased mortality in the ESRD population. During the quarter, the Company also introduced ImmunePrepTM, a development-stage...